



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/48	A1	(11) International Publication Number: WO 95/16438 (43) International Publication Date: 22 June 1995 (22.06.95)
(21) International Application Number: PCT/GB94/02703 (22) International Filing Date: 12 December 1994 (12.12.94) (30) Priority Data: 9325445.6 13 December 1993 (13.12.93) GB (71) Applicant (for all designated States except US): CORTECS LIMITED [GB/GB]; The Old Blue School, Lower Square, Isleworth, Middlesex TW7 6RL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BARNWELL, Stephen, George [GB/GB]; 30 Alun Crescent, Chester CH4 8HN (GB). HIGGINBOTTOM, Simon [GB/GB]; 4 Scotton Avenue, Little Sutton, South Wirral L66 4TJ (GB). WHELAN, Ian, Peter [GB/GB]; Townfoot Cottage, Talkin, Carlisle, Cumbria (GB). BURNS, Stephen, John [GB/GB]; 51 Wimberry Drive, Waterhayes Village, Newcastle-Under-Lyme ST5 7SG (GB). (74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strodé, 30 John Street, London WC1N 2DD (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, LR, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: BIPHASIC CAPSULE FORMULATION		
(57) Abstract		
<p>Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that two different formulations can be provided in a single capsule without one of the formulations having an adverse effect on the other.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Biphasic capsule formulation

The present invention relates to improved capsule formulations, in particular biphasic capsule formulations.

WO-A-9206680 discloses biphasic release formulations for lipophilic drugs comprising a C_{12} - C_{24} fatty acid and a pharmaceutically active substance. A portion of the formulation is formulated for non-sustained release and is generally in liquid form and a portion is formulated for sustained release on non-parenteral administration and will generally be a solid.

The formulations are extremely effective for the administration of lipophilic pharmaceutically active substances greatly enhancing oral bioavailability of propranolol. These results have been published (Barnwell *et al*, J. Controlled Release, 28, 306-309 (1994)), but it has been discovered that there are certain problems with the stability of the compositions even when stored at ambient temperature.

After capsules containing biphasic formulations such as those described in WO-A-9206680 have been stored for periods of greater than 3 months at ambient temperature, there is a decline in in vitro dissolution performance compared with initial values. The level of propranolol released from the formulation after 12 months' storage at ambient temperature was found to be reduced by 50% compared with initial values. In contrast, prolonged storage of capsules containing only the liquid rapid-release phase and capsules containing only the solid sustained release phase did not result in any change in

dissolution profile. This unstable release profile is therefore a problem only with biphasic formulations and represents a serious drawback in the development of such formulations since, clearly, a pharmaceutical formulation which is not stable under ambient storage conditions is of limited use in practice.

On investigation, it appeared that the deterioration in the release profile had arisen because, unexpectedly, the two phases of the formulation had become mixed during the storage of the capsules and the mixing of the phases had caused the release characteristics of both parts of the formulation to deteriorate. Deterioration was characterised by a visible intermixing between the two phases and a decline in *in vitro* dissolution performance. The rate of intermixing between the liquid rapid and solid sustained-release phases of the formulation was accelerated at elevated storage temperatures, eg 37°C, but much reduced at 4°C.

Therefore, in a first aspect of the invention there is provided a pharmaceutical formulation comprising a capsule containing at least two fill compositions, characterised in that the compositions are prevented from mixing with one another.

The capsule fill compositions may be compositions comprising C₁₂-C₂₄ fatty acids such as those disclosed in WO-A-9206680. The invention is particularly useful when one of the fill compositions is a solid and one a liquid, especially when the solid component also comprises glycerides, for example the GELUCIRE™ mixture disclosed in Example 1 of WO-A-9206680. In that case, the fatty acids tend to dissolve the lower molecular weight lipids

of the solid composition so that they gradually mix with the liquid composition. The progressive solubilisation of the lower molecular weight glycerides into the liquid composition slows down the rapid release characteristics of the liquid phase. It also leaves in the solid phase only the higher molecular weight glyceride components which do not easily erode to allow the release of the remaining fatty acid and the active material. An example of a modified capsule would be an adaptation of the potato starch Capill® capsules manufactured by Capsugel Limited. In this case, the starch capsule would be manufactured with a central partition and two open ends. This would allow two separate formulation components to be filled, each end of the capsule being sealed by the usual potato starch cap. Thus the sustained release of the active material from the solid component is retarded. These changes in drug release may be monitored using an in vitro dissolution method such as that described in Example 2 below.

However, there may be other reasons for wishing to separate the two fill compositions, for example they may contain different active compounds or different excipients which interact in an unfavourable manner and therefore the present invention is not limited to compositions such as those described in WO-A-9206680.

For example, with compositions such as those disclosed in GB Application No 9417524.7 there is the possibility of unfavourable interaction of the active ingredient, particularly if it is a protein, and the pH modifying agent (for instance, carbonate or bicarbonate). Thus, the present invention is particularly useful for such formulations.

The simplest method of preventing phase mixing is to formulate both of the fill compositions as solids but of course this will not be possible in all cases. Therefore, it is often desirable to provide some sort of physical barrier within the capsule to prevent mixing of the fill compositions.

However, there are problems with this approach. One problem is that the placing of a physical barrier between two compositions in a capsule often leads to the collapse of the capsule walls and any barrier which has this effect is of no use whatever.

Secondly, it is important to ensure that any material used as a physical barrier between fill compositions in a capsule does not interact with the fill compositions themselves. One solution which may overcome this problem is to provide a barrier of the same material as the capsule. This may be achieved by manufacturing capsules having two compartments and will be particularly effective for hard gelatin capsules and starch capsules.

In some cases, it will not be possible to manufacture the barrier from the same material as the capsule shell. There may be a variety of reasons for this, for example the difficulties in manufacturing a two-compartment capsule and the weakness in the capsule wall which a central barrier within the capsule may introduce. In addition, for soft gelatin capsules, the capsule walls may not be strong enough to support a central barrier in the capsule.

In such cases a barrier must be introduced into the capsule after manufacture and this will usually be done

as the capsule is filled. This will retain the advantage of low manufacturing cost of the capsules whilst still separating the fill compositions and preventing them from mixing.

5

The choice of material for the barrier is important and several factors must be taken into account. For example, if hydrophobic fill compositions are used, it may be desirable to use a hydrophilic material as a barrier between the fill compositions. On the other hand, if the fill compositions are hydrophilic in nature, then a hydrophobic material will be more suitable.

10

It is also highly desirable that the material used as a barrier should have a melting point such that it is a solid at any likely storage temperature. Therefore, the melting point should, at the least, be higher than 25°C (room temperature) but it is much preferred that the material should not begin to melt until it reaches about 37°C (body temperature).

15

20

A barrier formed from such a material has the advantage of easy formation since the barrier material can simply be filled into the capsules in a molten state at a temperature above its melting point and then allowed to cool and form a solid barrier. The barrier material will be added to the capsule after the first fill composition has been put into the capsule but before the addition of the second fill composition so as to form an effective barrier between the two compositions.

25

30

If the capsule is required to contain more than two fill compositions then layers of the barrier material can be added to the capsule between additions of the different

fill compositions.

In addition, the barrier material must, of course, be physiologically compatible since it is to be included in a pharmaceutical formulation.

Materials which have been found to be particularly useful as barrier materials in capsules are glycerides having a transition temperature (melting point) above 37°C. Suitable glycerides include di- and tri-glycerides, such as many of the various GELUCIRE compounds, which are hydrogenated fatty acid esters available from Gattefosse. (The word GELUCIRE is a trade mark.) Other trade marks of suitable glycerides include LABRAFIL and PRECIROL. GELUCIRE compounds and other suitable compounds having transition temperatures of from 40°C to 70°C are preferred. Specific examples of exemplary GELUCIRE compounds, and their equivalents include:

GELUCIRE 44/14
GELUCIRE 50/02
GELUCIRE 50/13
GELUCIRE 54/02 (also available as PRECIROL)
GELUCIRE 62/05 and
GELUCIRE 64/02 (also available as PRECIROL WL 2155).

The first two digits in the numeric portion of the GELUCIRE name represent the liquid/solid phase transition temperature in degrees centigrade and the second two digits represent the hydrophile/lipophile balance (HLB) value.

GELUCIRE 44/14 has a high HLB value and is therefore relatively hydrophilic. This means that it is

particularly useful as a barrier in capsules containing lipophilic fill compositions such as those described in WO-A-9206680 since it will be immiscible with both of the fill compositions.

5

The other compounds are more suitable for use in capsules with a hydrophilic fill since they are all relatively lipophilic.

10

A further use for the hydrophilic phase barrier may be to allow the formulation of a hydrophilic drug for co-administration with the lipophilic delivery system described in WO-A-9206680. An example of this application is the formulation and delivery of a non-membrane damaging bile acid (a hydrophilic material) as described in WO-A-9325192 together with a lipophilic drug in the lipophilic delivery system described in WO-A-9206680. The advantage of this arrangement is for the improved delivery of drugs which undergo both high hepatic first-pass metabolism and enterohepatic recycling (e.g. haloperidol, chlorpromazine and morphine) or where the non-membrane damaging bile acid can attenuate the toxic effects of a drug subject to high first-pass metabolism and formulated as described in WO-A-9206680.

25

Conversely, where a lipophilic barrier is used to separate hydrophilic phases it may act as a reservoir for a co-administered lipophilic drug.

30

Another way in which intermixing may be prevented with the biphasic rapid and sustained-release formulations described in WO-A-9206680 containing C_{12} to C_{24} fatty acids, is to ensure that the rapid-release phase remains a solid at normal storage temperature, e.g. below 30°C.

This may be achieved by mixing a hydrophobic Gelucire® with a melting point above 30°C, exemplified by Gelucire 33/01, with the molten rapid release component before filling into capsules, the rapid-release phase solidifying on cooling and thus being unable to undergo mixing with the resident solid sustained-release formulation component. An example of this formulation approach is given below in Example 3.

It is preferred that hard gelatin capsules are used and, in that case, liquid fill compositions may contain gelatin softening agents such as those described in WO-A-9102520. Suitable gelatin softening agents can be found by reference to the art of manufacturing soft gelatin capsules where such materials are incorporated into the mix which forms the gelatin wall. Particularly suitable gelatin softening agents include glycerol, propylene glycol, glycerol mono-oleate and sorbitol.

The capsules may be enteric coated or otherwise protected to ensure better survival of the pharmaceutically active compound through the stomach. Any convenient enteric protection method may be used. Capsules containing the formulation may be coated with an enteric coat such as hydroxypropylmethylcellulose phthalate or by the commercial coating process of Pharma-Vinci A/S (Denmark).

The formulations of the invention may be prepared by any suitable process but when a solid barrier material is used then the process may comprise filling the first fill composition, the barrier material and the second fill composition sequentially into a suitable capsule.

Therefore, in a further aspect of the invention, there is

provided a process for the preparation of a capsule containing at least two fill compositions separated by a barrier material, the process comprising filling a first fill composition, the barrier material and a second fill composition sequentially into a suitable capsule.

Preferred barrier materials are as described above.

The capsule may be of any suitable material, for example hard gelatin capsules, soft gelatin capsules and starch capsules but gelatin capsules are preferred, particularly hard gelatin capsules.

The invention will now be further described with reference to the following examples which are not intended to be limiting.

EXAMPLE 1 - Biphasic Propranolol Formulation with Phase Barrier

The following example is a biphasic rapid and sustained-release propranolol formulation similar to that described in WO 92/06680. Typically these materials melt upon heating, thereby allowing the use of conventional mixing and pumping technology for fluid filling.

A.	<u>Sustained-Release Phase</u>	<u>mg/capsule</u>
	Propranolol	40.0
	Oleic Acid BP	102.1
	Colloidal silicon dioxide (Aerosil 200)	8.2
	Polyoxyl-40-hydrogenated castor oil NF (Cremophor RH40)	27.2

10

Saturated polyglycolysed glycerides Ph.F. 94.5
(Gelucire 50/02)

5 B. Phase Barrier

Saturated polyglycolysed glycerides Ph.F. 150.0
(Gelucire 44/14)

10 C. Rapid-Release Phase

Propranolol base 40.0

15 Oleic acid BP 110.0

20 A. Sustained-Release Phase

The oleic acid, Gelucire 50/02 and Cremophor were heated to 50°C-55°C until a clear solution was obtained. Propranolol base was added with stirring, while maintaining the temperature of the mix at 50°C and continued until the propranolol base was fully dissolved. Finally Aerosil was added while stirring. A total of 272 mg of the formulation was filled into size 0 hard gelatin capsules while hot and then allowed to solidify with cooling.

B. Phase Barrier

The Gelucire 44/14 was heated until fully melted at 45°C-55°C and 150 mg filled over the sustained-release phase, previously filled into size 0 hard gelatin capsules, and allowed to solidify with cooling.

40

C. Rapid-Release Phase

Oleic acid was heated with stirring at 45°C-50°C. Propranolol base was added and dissolved with stirring and allowed to cool. A total of 150 mg of the liquid rapid-release formulation was then filled over the phase barrier. The resulting capsules contained a solid sustained-release phase, solid phase separation barrier and liquid rapid-release phase. The capsules were then sealed by gelatin banding. Following gelatin banding, the capsules may be enteric-coated as described in WO 92/06680.

EXAMPLE 2 - Dissolution Studies With and Without Phase Barrier System

For evaluating the dispersion behaviour of the experimental formulations, a test-method was devised based upon the USP XXII dissolution test for tablets and capsules. The aim of the test was to subject the samples to an environment similar to that in the intestine. Dispersion in 5 hours was selected as a satisfactory total release time for the test samples. This was based on the understanding that lymphatic absorption occurs predominantly in the small intestine.

The dissolution apparatus as specified by the USP XXII (apparatus 2) was used with Sorensens phosphate buffer, pH 6.8 containing 0.2% sodium cholate and 0.1% sodium deoxycholate, equilibrated to 37°C. The total volume of buffer added to each dissolution vessel was 900 ml, with a paddle rotation speed of 70 rpm. The paddle height was adjusted so that the top edge of the blade was level with the surface of the liquid. The test sample was dropped

into the dissolution medium and the rotation of the paddle started. The test sample was allowed to float freely at the liquid surface throughout the test. At each time-point, a 5 ml aliquot of the dissolution medium was removed and replaced with 5 ml of fresh buffer solution. Each 5 ml sample was initially filtered through a 1.2 μ M coarse filter and subsequent 1.2 μ M fine filter. The absorbance of the filtered solution was then determined at 290nm using a UV at 290 nm using a UV spectrophotometer. The propranolol concentration in the dissolution medium was calculated using a pre-determined calibration curve for propranolol.

A = Example 1 with phase barrier.

B = Example 1 without phase barrier.

Table 1 - 30°C Storage

% Propranolol Release						
Time (minutes)	Initial		3 Months		7 Months	
	A	B	A	B	A	B
15	36	44	39	30	34	23
30	41	53	51	38	45	29
60	49	60	57	47	50	35
120	58	64	64	61	55	43
300	77	71	78	71	69	59

Table 2 - 37°C Storage

% Propranolol Release				
Time (minutes)	Initial		1 Month	
	A	B	A	B
15	36	44	26	15
30	41	53	44	25
60	49	60	48	37
120	58	64	51	45
300	77	71	62	54

As is clear from the results shown in Tables 1 and 2 the presence of a barrier between the solid sustained release phase and the liquid phase improves considerably the amount of propranolol released, particularly from the sustained release phase. The effect of the barrier increases with the length of time for which the capsules are stored.

EXAMPLE 3 - Biphasic Propranolol Formulation with Solid Rapid-Release Phase

This is an example of a biphasic rapid and sustained-release propranolol formulation based on that described in WO-A-9206680, except that phase intermixing is prevented by having a solid rapid-release phase. The rapid-release phase is formulated as a solid, using Gelucire® 33/01, which melts on heating above 30°C allowing (i) capsule filling to take place using conventional mixing and pumping technology, and (ii)

enables rapid-release to take place at normal temperature.

A. Sustained-Release Phase mg/capsule

5 As for Example 1 272.0

10 B. Solid Rapid-Release Phase

 Propranolol base 40.0

 Oleic acid B.P. 110.0

15 Saturated polyglycolysed glycerides Ph.F. 150.0
 (Gelucire® 33/01)

20 The modified rapid-release phase was manufactured by heating oleic acid at 45-50°C with stirring. Propranolol base and Gelucire® 33/01 were added with stirring until completely dissolved. The molten rapid-release phase was
25 maintained above 37°C until filled into capsules already containing the solid sustained-release phase described in Example 1. A total of 300 mg of the modified sustained-release phase containing Gelucire® 33/01 was filled into
30 size 0 hard gelatin capsules while hot and then allowed to solidify with cooling. The capsules were then sealed by gelatin banding. Following gelatin banding, the capsules may be enteric-coated as described in WO-A-9206680 and Burns et al, International Journal of Pharmaceutics, 110: 291-296 (1994).

EXAMPLE 4 - Dissolution Studies Using Solid Rapid-Release Phase System

The same dissolution method as described in Example 2 was used to evaluate capsules containing the biphasic rapid and sustained-release preparation described in Example 3.

Table 3 - 25°C Storage

% Propranolol Release			
Time (minutes)	Initial	2 Months	12 Months
15	32	26	23
30	52	49	50
60	60	61	64
120	65	67	71
300	75	83	82

Table 4 - 30°C Storage

% Propranolol Release				
Time (minutes)	Initial	1 Month	2 Months	12 Months
15	32	22	27	14
30	52	43	54	37
60	60	59	62	66
120	65	64	80	76
300	75	84	85	77

The results in Table 3 show that at 25°C the dissolution profile of a biphasic formulation is maintained for at least 12 months. Table 4 shows that at 30°C, close to the melting point of the modified rapid-release phase containing Gelucire® 33/01, there is a small deterioration in initial release rate. However, the overall biphasic release characteristics of the formulation are maintained.

CLAIMS

1. A pharmaceutical formulation comprising a capsule containing at least two fill compositions, characterised in that the compositions are prevented from mixing with one another.
2. A pharmaceutical formulation as claimed in claim 1, wherein both of the fill compositions are solid.
3. A pharmaceutical formulation as claimed in claim 1, wherein the two fill compositions are separated by a physical barrier.
4. A formulation as claimed in claim 3, wherein the barrier is of the same material as the capsule.
5. A formulation as claimed in claim 3, wherein the barrier comprises a material having a melting point higher than 25°C.
6. A formulation as claimed in claim 5, wherein the barrier comprises a material having a melting point of higher than 37°C.
7. A formulation as claimed in any one of claims 3 to 6, wherein the fill compositions are hydrophobic in nature and the barrier comprises a hydrophilic material.
8. A formulation as claimed in any one of claims 3 to 6, wherein the fill compositions are hydrophilic in nature and the barrier comprises a hydrophobic material.
9. A pharmaceutical formulation as claimed in any one

of claims 3 to 8, wherein the barrier comprises a glyceride, for example a di- or tri-glyceride, or a mixture of glycerides.

- 5 10. A composition as claimed in claim 9, wherein the barrier material comprises a hydrogenated fatty acid ester or a mixture of esters, available under one of the following trade marks:

10 GELUCIRE 44/14
GELUCIRE 50/13
GELUCIRE 50/02
GELUCIRE 54/02 (also available as PRECIROL)
GELUCIRE 62/05 and
15 GELUCIRE 64/02 (also available as PRECIROL WL 2155).

11. A formulation as claimed in any one of claims 3 to 10 comprising a first fill composition comprising a C_{12} - C_{24} fatty acid and a pharmaceutically active substance,
20 formulated for non-sustained release on non-parenteral administration; and a second fill composition comprising a C_{12} - C_{24} fatty acid and a pharmaceutically active substance formulated for sustained release of the active substance on non-parenteral administration.

- 25 12. A formulation as claimed in claim 11, wherein the first and the second fill compositions are hydrophobic in nature and the barrier is formed from a mixture of hydrogenated fatty acid esters sold under the trade mark
30 GELUCIRE 44/14.

13. A formulation as claimed in any one of claims 1 to 6 or any one of claims 8 to 10 comprising a first fill composition comprising a biologically active material and

a bile acid salt and a second fill composition comprising an agent adapted to adjust the pH of the gut to a pH value of from 7.5 to 9.

- 5 14. A formulation as claimed in claim 13 wherein the biologically active material is a protein such as insulin, calcitonin, a growth hormone, an interferon, an interleukin or an active fragment of any of these.
- 10 15. A formulation as claimed in claim 13 or claim 14 wherein the buffering agent comprises carbonate and/or bicarbonate ions.

AMENDED CLAIMS

[received by the International Bureau on 2 June 1995 (02.06.95);
original claims 1 and 3 amended;
original claim 2 unchanged;
original claim 4 cancelled;
original claims 5-15 renumbered
into new claims 4-14. (3 pages)]

1. A pharmaceutical formulation comprising a capsule
having a single compartment containing at least two fill
5 compositions, characterised in that the compositions are
prevented from mixing with one another.

2. A pharmaceutical formulation as claimed in claim 1,
wherein both of the fill compositions are solid.

10 3. A pharmaceutical formulation as claimed in claim 1,
wherein the two fill compositions are separated by a
physical barrier comprising a further fill composition of
a different material to that of the capsule.

15 4. A formulation as claimed in claim 3, wherein the
barrier comprises a material having a melting point
higher than 25°C.

20 5. A formulation as claimed in claim 4, wherein the
barrier comprises a material having a melting point of
higher than 37°C.

25 6. A formulation as claimed in any one of claims 3 to
5, wherein the fill compositions are hydrophobic in
nature and the barrier comprises a hydrophilic material.

30 7. A formulation as claimed in any one of claims 3 to
5, wherein the fill compositions are hydrophilic in
nature and the barrier comprises a hydrophobic material.

8. A pharmaceutical formulation as claimed in any one
of claims 3 to 7, wherein the barrier comprises a
glyceride, for example a di- or tri-glyceride, or a

mixture of glycerides.

9. A composition as claimed in claim 8, wherein the barrier material comprises a hydrogenated fatty acid ester or a mixture of esters, available under one of the following trade marks:

GELUCIRE 44/14
GELUCIRE 50/13
10 GELUCIRE 50/02
GELUCIRE 54/02 (also available as PRECIROL)
GELUCIRE 62/05 and
GELUCIRE 64/02 (also available as PRECIROL WL 2155).

- 15 10. A formulation as claimed in any one of claims 3 to 9 comprising a first fill composition comprising a C_{12} - C_{24} fatty acid and a pharmaceutically active substance, formulated for non-sustained release on non-parenteral administration; and a second fill composition comprising
20 a C_{12} - C_{24} fatty acid and a pharmaceutically active substance formulated for sustained release of the active substance on non-parenteral administration.

- 25 11. A formulation as claimed in claim 10, wherein the first and the second fill compositions are hydrophobic in nature and the barrier is formed from a mixture of hydrogenated fatty acid esters sold under the trade mark GELUCIRE 44/14.

- 30 12. A formulation as claimed in any one of claims 1 to 5 or any one of claims 7 to 9 comprising a first fill composition comprising a biologically active material and a bile acid salt and a second fill composition comprising an agent adapted to adjust the pH of the gut to a pH

value of from 7.5 to 9.

13. A formulation as claimed in claim 12 wherein the
biologically active material is a protein such as
5 insulin, calcitonin, a growth hormone, an interferon, an
interleukin or an active fragment of any of these.

14. A formulation as claimed in claim 12 or claim 13
wherein the buffering agent comprises carbonate and/or
10 bicarbonate ions.

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/GB 94/02703

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,39 24 887 (KUBIN H.) 5 April 1990 see the whole document ---	1-6
X	EP,A,0 211 079 (FUJISAWA PHARMACEUTICAL CO LTD) 25 February 1987 see page 2, line 15 - line 23 see page 11, line 6 - line 21 see page 13 - page 14; example 1 see page 16; example 6 ---	1-6
X	EP,A,0 308 637 (STEPHAN D. ET AL) 29 March 1989 see page 2, column 1, line 54 - page 2, column 2, line 27 see page 3, column 3, line 17 - line 31 --- -/--	1,3-6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 April 1995

Date of mailing of the international search report

25. 04. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/GB 94/02703

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 06680 (CORTECS LTD) 30 April 1992 cited in the application see page 20, line 10 - line 22 see page 21 - page 23; example 1 ---	10-12
A	WO,A,90 12583 (CORTECS LTD) 1 November 1990 see page 45; example 51 -----	13

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/GB 94/02703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-3924887	05-04-90	NONE	
EP-A-0211079	25-02-87	WO-A- 8604501	14-08-86
EP-A-0308637	29-03-89	DE-A- 3727894	02-03-89
WO-A-9206680	30-04-92	AU-B- 656924	23-02-95
		AU-A- 8731591	20-05-92
		BG-A- 97644	25-04-94
		CZ-A- 9300641	19-01-94
		EP-A- 0553178	04-08-93
		HU-A- 64215	28-12-93
		JP-T- 6502143	10-03-94
		US-A- 5391377	21-02-95
WO-A-9012583	01-11-90	AU-A- 5541290	16-11-90